You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin

Alerts

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address